All In Biotech

Drug Trial Radar · NCT06208241

Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Jul 12, 2023

Primary completion

Sep 25, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Amir OronAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Enlivex Therapeutics Ltd.
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pilot study to assess safety and possible efficacy of Allocetra-OTS in end-stage knee osteoarthritis.

Conditions

  • Knee Osteoarthritis

Interventions

  • Allocetra-OTSDrug

    Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injectionTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaplan Medical Center

    Rehovot, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.